|
||||||
|
 | |
| |
| Expression of this gene in the resistant group across all datasets and cell types |
| Significant ligand-receptor pairs related to this gene (This gene does not contain this module) |
| |
| |
| |
| Acts as a transcription factor (This gene does not contain this module) |
|
Gene: ABL1 |
Summary for ABL1 |
| Gene information | Gene symbol | ABL1 | Ensembl ID | ENSG00000097007 |
| Entrez ID | 25 | |
| Gene name | ABL proto-oncogene 1, non-receptor tyrosine kinase | |
| Synonyms | ABL|c-ABL|JTK7|p150 | |
| Gene type | protein_coding | |
| UniProtAcc | P00519 |
Top |
Dataset with differentially expressed gene: ABL1 |
 Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE131984_Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | palbociclib | NA | Malignant cells | 0.250039 | 3.28e-08 |
Top |
Expression of ABL1 in the resistant group across all datasets and cell types |
| Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.) |
 |
Top |
Significant ligand-receptor pairs related to ABL1 |
| This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.) |
Top |
Known drug resistance mechanisms of this gene |
| This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information. |
| Gene symbol | Mechanism |
ABL1 | Aberration of the Drug's Therapeutic Target |
ABL1 | Epigenetic Alteration of DNA, RNA or Protein |
ABL1 | Unusual Activation of Pro-survival Pathway |
| Page: 1 |
Top |
MicroRNAs (miRNA) regulating ABL1 |
| This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | miRNA | Score | GeneBank accession |
| ABL1 | hsa-miR-30a-5p | 91.4296 | NM_005157 |
| ABL1 | hsa-miR-30e-5p | 91.4296 | NM_005157 |
| ABL1 | hsa-miR-30b-5p | 91.4296 | NM_005157 |
| ABL1 | hsa-miR-30d-5p | 91.4296 | NM_005157 |
| ABL1 | hsa-miR-30c-5p | 91.4296 | NM_005157 |
| ABL1 | hsa-miR-4320 | 89.9547 | NM_005157 |
| ABL1 | hsa-miR-3922-5p | 89.6899 | NM_005157 |
| ABL1 | hsa-miR-5004-3p | 85.0462 | NM_005157 |
| ABL1 | hsa-miR-6847-5p | 83.3001 | NM_005157 |
| ABL1 | hsa-miR-196b-5p | 83.2407 | NM_005157 |
| ABL1 | hsa-miR-196a-5p | 83.2407 | NM_005157 |
| ABL1 | hsa-miR-8084 | 83.2158 | NM_005157 |
| ABL1 | hsa-miR-891a-3p | 82.7116 | NM_005157 |
| ABL1 | hsa-miR-1185-1-3p | 82.2388 | NM_005157 |
| ABL1 | hsa-let-7f-2-3p | 82.2388 | NM_005157 |
| ABL1 | hsa-miR-1185-2-3p | 82.2388 | NM_005157 |
| ABL1 | hsa-miR-6859-3p | 82.1992 | NM_005157 |
| ABL1 | hsa-miR-29a-5p | 80.3327 | NM_005157 |
| ABL1 | hsa-miR-3194-3p | 80.0249 | NM_005157 |
| Page: 1 |
Top |
Motifs and transcription factors (TFs) regulating ABL1 |
| This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | motif | TF_highConf |
| ABL1 | taipale_tf_pairs__HOXB13_ONECUT2_NNNRTAAAWATYGAYY_CAP | HOXB13; ONECUT2 (directAnnotation). |
| ABL1 | transfac_pro__M01835 | KLF4 (directAnnotation). |
| ABL1 | transfac_pro__M07270 | TEAD4 (directAnnotation). |
| Page: 1 |
Top |
Acts as a transcription factor |
| This table shows that this differential gene acts as a transcription factor. |
Top |
Acts as a drug target |
| This table shows that this differential gene acts as a drug target. |
| Target name | Drug name | Drug ID | Drug type |
| ABL1 | "1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA" | DB08043 | small molecule |
| ABL1 | "2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide" | DB08583 | small molecule |
| ABL1 | "2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE" | DB07831 | small molecule |
| ABL1 | "5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE" | DB08350 | small molecule |
| ABL1 | "Asciminib" | DB12597 | small molecule |
| ABL1 | "ATP" | DB00171 | small molecule |
| ABL1 | "Bosutinib" | DB06616 | small molecule |
| ABL1 | "Brigatinib" | DB12267 | small molecule |
| ABL1 | "Dasatinib" | DB01254 | small molecule |
| ABL1 | "Fostamatinib" | DB12010 | small molecule |
| ABL1 | "Imatinib" | DB00619 | small molecule |
| ABL1 | "Myristic acid" | DB08231 | small molecule |
| ABL1 | "N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide" | DB03878 | small molecule |
| ABL1 | "Nilotinib" | DB04868 | small molecule |
| ABL1 | "PD-166326" | DB08339 | small molecule |
| ABL1 | "Ponatinib" | DB08901 | small molecule |
| ABL1 | "Radotinib" | DB12323 | small molecule |
| ABL1 | "Regorafenib" | DB08896 | small molecule |
| ABL1 | "Umbralisib" | DB14989 | small molecule |
| ABL1 | "XL228" | DB05184 | small molecule |
| Page: 1 |
| 1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
| 2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |
| 1 | Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationNature. |
| 2 | Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy |
| 3 | Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol |
| 4 | Exploiting Temporal Collateral Sensitivity in Tumor Clonal EvolutionCell |
| 5 | Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |